Spinocerebellar ataxia type 14: refining clinicogenetic diagnosis in a rare adult-onset disorder.


Journal

Annals of clinical and translational neurology
ISSN: 2328-9503
Titre abrégé: Ann Clin Transl Neurol
Pays: United States
ID NLM: 101623278

Informations de publication

Date de publication:
04 2021
Historique:
revised: 29 12 2020
received: 17 09 2020
accepted: 13 01 2021
pubmed: 20 3 2021
medline: 12 1 2022
entrez: 19 3 2021
Statut: ppublish

Résumé

Genetic variant classification is a challenge in rare adult-onset disorders as in SCA-PRKCG (prior spinocerebellar ataxia type 14) with mostly private conventional mutations and nonspecific phenotype. We here propose a refined approach for clinicogenetic diagnosis by including protein modeling and provide for confirmed SCA-PRKCG a comprehensive phenotype description from a German multi-center cohort, including standardized 3D MR imaging. This cross-sectional study prospectively obtained neurological, neuropsychological, and brain imaging data in 33 PRKCG variant carriers. Protein modeling was added as a classification criterion in variants of uncertain significance (VUS). Our sample included 25 cases confirmed as SCA-PRKCG (14 variants, thereof seven novel variants) and eight carriers of variants assigned as VUS (four variants) or benign/likely benign (two variants). Phenotype in SCA-PRKCG included slowly progressive ataxia (onset at 4-50 years), preceded in some by early-onset nonprogressive symptoms. Ataxia was often combined with action myoclonus, dystonia, or mild cognitive-affective disturbance. Inspection of brain MRI revealed nonprogressive cerebellar atrophy. As a novel finding, a previously not described T2 hyperintense dentate nucleus was seen in all SCA-PRKCG cases but in none of the controls. In this largest cohort to date, SCA-PRKCG was characterized as a slowly progressive cerebellar syndrome with some clinical and imaging features suggestive of a developmental disorder. The observed non-ataxia movement disorders and cognitive-affective disturbance may well be attributed to cerebellar pathology. Protein modeling emerged as a valuable diagnostic tool for variant classification and the newly described T2 hyperintense dentate sign could serve as a supportive diagnostic marker of SCA-PRKCG.

Identifiants

pubmed: 33739604
doi: 10.1002/acn3.51315
pmc: PMC8045942
doi:

Substances chimiques

protein kinase C gamma EC 2.7.1.-
Protein Kinase C EC 2.7.11.13

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

774-789

Informations de copyright

© 2021 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.

Références

Neurology. 2006 Jun 13;66(11):1717-20
pubmed: 16769946
Lancet Neurol. 2013 Jul;12(7):650-8
pubmed: 23707147
Mov Disord. 2007 Jan 15;22(2):265-7
pubmed: 17149711
BMC Neurol. 2013 Nov 29;13:186
pubmed: 24289098
Ann Neurol. 2005 Nov;58(5):720-9
pubmed: 16193476
Mol Cell Neurosci. 2019 Jul;98:46-53
pubmed: 31158466
Nucleic Acids Res. 2014 Jul;42(Web Server issue):W252-8
pubmed: 24782522
Mol Brain. 2017 Jul 24;10(1):34
pubmed: 28738819
Mov Disord. 2007 May 15;22(7):1024-6
pubmed: 17343273
Acta Neuropathol Commun. 2018 Sep 24;6(1):99
pubmed: 30249303
J Neurol. 2006 Aug;253(8):1111-2
pubmed: 16649092
J Cell Sci. 2008 Jul 15;121(Pt 14):2339-49
pubmed: 18577575
Cerebellum. 2017 Apr;16(2):577-594
pubmed: 27734238
Am J Hum Genet. 2003 Apr;72(4):839-49
pubmed: 12644968
Mov Disord. 2016 Apr;31(4):436-57
pubmed: 27079681
Hum Mol Genet. 2009 Oct 1;18(19):3533-43
pubmed: 19561170
Mov Disord. 2006 Sep;21(9):1355-60
pubmed: 16763984
Gait Posture. 2016 Jul;48:194-201
pubmed: 27289221
Curr Opin Neurol. 2011 Aug;24(4):339-45
pubmed: 21734495
Cerebellum. 2015 Apr;14(2):175-96
pubmed: 25382714
Mov Disord. 2016 Apr;31(4):458-70
pubmed: 26899883
Cerebellum. 2020 Aug;19(4):469-482
pubmed: 32338350
Parkinsonism Relat Disord. 2018 Jul;52:119-120
pubmed: 29609848
Mov Disord. 2018 Jul;33(7):1119-1129
pubmed: 29603387
JAMA Neurol. 2018 May 1;75(5):591-599
pubmed: 29482223
Cerebellum. 2014 Feb;13(1):89-96
pubmed: 24030789
AJNR Am J Neuroradiol. 2017 Aug;38(8):1467-1474
pubmed: 28408628
Arch Neurol. 2003 Dec;60(12):1749-51
pubmed: 14676051
J Neurol. 2004 Jun;251(6):740-6
pubmed: 15311352
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
Cerebellum. 2013 Jun;12(3):418-28
pubmed: 23090211
Neurology. 2012 Jul 10;79(2):127-31
pubmed: 22675081
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Clin Radiol. 2016 Jan;71(1):107-19
pubmed: 26577296
Adv Neurol. 1986;43:33-55
pubmed: 3080851
Neurol Genet. 2018 Oct 24;4(6):e279
pubmed: 30533525
Ann Neurol. 2000 Aug;48(2):156-63
pubmed: 10939565
J Neurol Neurosurg Psychiatry. 2018 May;89(5):488-492
pubmed: 29089396
Eur J Radiol. 2019 Jan;110:187-192
pubmed: 30599859
Int J Geriatr Psychiatry. 2004 Feb;19(2):136-43
pubmed: 14758579
Cerebellum. 2007;6(3):159-62
pubmed: 17786810
Cerebellum. 2016 Jun;15(3):369-91
pubmed: 26105056
Mov Disord. 2006 Jul;21(7):1025-8
pubmed: 16547918
J Biol Chem. 2008 Jul 11;283(28):19854-63
pubmed: 18499672
Neuropsychologia. 1971 Mar;9(1):97-113
pubmed: 5146491
Neurology. 2000 Mar 28;54(6):1350-6
pubmed: 10746609
Mov Disord. 2007 Oct 31;22(14):2135-6
pubmed: 17708558
Neurology. 2009 Feb 24;72(8):750-9
pubmed: 19237705
Neuroradiology. 2020 Sep;62(9):1095-1103
pubmed: 32285148
Eur J Neurol. 2014 Apr;21(4):552-62
pubmed: 24418350
Lancet Neurol. 2010 Sep;9(9):885-94
pubmed: 20723845
Neurology. 2003 Dec 23;61(12):1760-5
pubmed: 14694043
Neurology. 2006 Nov 28;67(10):1769-73
pubmed: 17130408
Arch Neurol. 2002 Aug;59(8):1291-5
pubmed: 12164726
Tremor Other Hyperkinet Mov (N Y). 2017 Oct 23;7:506
pubmed: 29123945
J Neurol. 2015 Aug;262(8):1927-35
pubmed: 26041613
Arch Neurol. 2004 Aug;61(8):1242-8
pubmed: 15313841
Clin Neurophysiol. 2017 Jan;128(1):253-259
pubmed: 27940047
Front Hum Neurosci. 2017 Dec 13;11:605
pubmed: 29326569
J Neuroinflammation. 2015 Sep 17;12:167
pubmed: 26377184
Neuroscience. 2008 May 2;153(2):507-17
pubmed: 18387748
J Hum Genet. 2005;50(10):523-529
pubmed: 16189624
Acta Neurol Scand. 2012 Feb;125(2):116-22
pubmed: 21434874

Auteurs

Tanja Schmitz-Hübsch (T)

NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health Berlin, Berlin, Germany.
Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.

Silke Lux (S)

Department of Psychiatry and Psychotherapy, University Hospital Bonn, Bonn, Germany.

Peter Bauer (P)

Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.
CENTOGENE AG, Rostock, Germany.

Alexander U Brandt (AU)

NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health Berlin, Berlin, Germany.
Department of Neurology, University of California, Irvine, CA, USA.

Elena Schlapakow (E)

Department of Neurology, University Hospital Bonn, Bonn, Germany.
Center for Rare Diseases, University of Bonn, Bonn, Germany.

Susanne Greschus (S)

Department of Radiology, University Hospital Bonn, Bonn, Germany.

Michael Scheel (M)

NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health Berlin, Berlin, Germany.
Department of Neuroradiology, Charité -Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.

Hanna Gärtner (H)

Institute of Neuroscience and Medicine (INM-1), Research Centre Juelich, Juelich, Germany.

Mehmet E Kirlangic (ME)

Institute of Neuroscience and Medicine (INM-1), Research Centre Juelich, Juelich, Germany.
Institute for Biomedical Engineering and Computer Science, Technische Universität Ilmenau, Ilmenau, Germany.

Vincent Gras (V)

Institute of Neuroscience and Medicine (INM-4), Research Centre Juelich, Juelich, Germany.

Dagmar Timmann (D)

Department of Neurology, Essen University Hospital, University of Duisburg-Essen, Essen, Germany.

Matthis Synofzik (M)

Department of Neurodegenerative Diseases, Center for Neurology, Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.

Alejandro Giorgetti (A)

Computational Biophysics, German Research School for Simulation Sciences, and Computational Biomedicine, Institute for Advanced Simulation (IAS-5) and Institute of Neuroscience and Medicine (INM-9), Research Centre Juelich, Juelich, Germany.
Department of Biotechnology, University of Verona, Verona, 37134, Italy.

Paolo Carloni (P)

Computational Biophysics, German Research School for Simulation Sciences, and Computational Biomedicine, Institute for Advanced Simulation (IAS-5) and Institute of Neuroscience and Medicine (INM-9), Research Centre Juelich, Juelich, Germany.

Jon N Shah (JN)

Institute of Neuroscience and Medicine (INM-4), Research Centre Juelich, Juelich, Germany.
Department of Neurology, Faculty of Medicine, JARA, RWTH Aachen University, Aachen, Germany.

Ludger Schöls (L)

Department of Neurodegenerative Diseases, Center for Neurology, Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.

Ute Kopp (U)

Klinik und Hochschulambulanz für Neurologie, Charité -Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.

Lisa Bußenius (L)

Institute of Neuroscience and Medicine (INM-1), Research Centre Juelich, Juelich, Germany.
Institute for Biochemistry and Molecular Cell Biology, Center for Experimental Medicine, University Clinic Hamburg Eppendorf, Hamburg, Germany.

Timm Oberwahrenbrock (T)

NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health Berlin, Berlin, Germany.

Hanna Zimmermann (H)

NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health Berlin, Berlin, Germany.

Caspar Pfueller (C)

NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health Berlin, Berlin, Germany.

Ella-Maria Kadas (EM)

NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health Berlin, Berlin, Germany.

Maria Rönnefarth (M)

Klinik und Hochschulambulanz für Neurologie, Charité -Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.

Anne-Sophie Grosch (AS)

Klinik und Hochschulambulanz für Neurologie, Charité -Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.

Matthias Endres (M)

NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health Berlin, Berlin, Germany.
Klinik und Hochschulambulanz für Neurologie, Charité -Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.
Center for Stroke Research Berlin (CSB), Charité - Universitätsmedizin Berlin, Berlin, Germany.
German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
German Centre for Cardiovascular Research (DZHK), Berlin, Germany.

Katrin Amunts (K)

Institute of Neuroscience and Medicine (INM-1), Research Centre Juelich, Juelich, Germany.
C. and O. Vogt Institute for Brain Research, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.

Friedemann Paul (F)

NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health Berlin, Berlin, Germany.
Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.
Klinik und Hochschulambulanz für Neurologie, Charité -Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.

Sarah Doss (S)

Klinik und Hochschulambulanz für Neurologie, Charité -Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.
Movement Disorders Section, Department of Neurological Sciences, University of Nebraska Medical Center, Omaha, NE, USA.

Martina Minnerop (M)

Institute of Neuroscience and Medicine (INM-1), Research Centre Juelich, Juelich, Germany.
Department of Neurology, Center for Movement Disorders and Neuromodulation, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.
Institute of Clinical Neuroscience and Medical Psychology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH